Zacks Investment Research on MSN1d
PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo
Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its RSV ...
Pharmaceutical Technology on MSN2d
Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSK
Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
Medical Dialogues1d
Pfizer Abrysvo gets European Commission nod for RSV Lower Respiratory Tract Disease in adults aged 18-59 years
Pfizer Inc. has announced that the European Commission (EC) has issued a decision amending the marketing authorization for ...
Pfizer announces European Commission approval of Abrysvo indication extension
Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s ...
Pfizer reports EC approval of amending marketing authorization of Abrysvo
Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s ...
Pfizer Gets Expanded European Approval of Abrysvo RSV Vaccine for All Adults
Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...
Pfizer (NYSE:PFE) Expands RSV Vaccine Use In Europe Amid 3% Share Price Dip
Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include ...
The Pharma Letter2d
EC amends authorization for Pfizer’s RSV vaccine Abrysvo
The European Commission (EC) has issued a decision amending the marketing authorization for Abrysvo, US pharma giant Pfizer’s ...
Nasdaq2d
Pfizer: ABRYSVO Now Approved In The EU To Prevent RSV In Adults Aged 18 And Older
(RTTNews) - Pfizer (PFE) announced the European Commission has issued a decision amending the marketing authorization for ABRYSVO, the company's bivalent respiratory syncytial virus prefusion F ...
Mirage News2d
EU Approves Pfizer's ABRYSVO RSV Vaccine for Adults 18-59
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the ...
Morningstar2d
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC ...